ICIs regulate CD8-positive T lymphocytes and regulatory T (Treg) cells by targeting the PD-1, PD-L1 and CTLA-4 pathways, thereby restoring the body’s tumor-suppressed immune function and enabling the body to produce an efficient immune response to tumor cells. The gene discussed is CD8A; the disease is neoplasm.